Thursday, 6 October 2022

BioLargo Secures Product Recovery Management (PRM) as Channel Partner and Contract Manufacturer for BioLargo’s Water Treatment Technologies

Westminster, CA – October 6, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that it signed a channel partnership agreement with Product Recovery Management, Inc. to sell and distribute BioLargo’s water treatment systems and act as a contract manufacturer.

Product Recovery Management (PRM) (https://www.prmfiltration.com/), based out of Butner, NC, is a UL-certified equipment integrator specializing in remediation services with over 40 years of history serving customers. PRM designs and manufactures treatment systems that address a wide variety of contamination challenges in the remediation and landfill industries, including PFAS contamination. Their Butner operations include a 250,000 square foot manufacturing facility with large-scale fabrication capabilities.

The channel partner agreement grants PRM a license to sell and distribute BioLargo’s innovative water and wastewater treatment technologies, including but not limited to the Aqueous Electrostatic Concentrator (AEC), BioLargo’s effective, affordable, low-waste solution for removing per- and polyfluoroalkyl substances (PFAS) from water. PRM will also be authorized to sell BioLargo’s Advanced Oxidation System (AOS) technology, the energy-efficient and affordable solution for simultaneous water disinfection and micropollutant treatment.

PRM will also be a contract manufacturer for BioLargo’s water treatment technologies, including the AEC, the AOS, as well as other treatment systems designed by BioLargo (e.g., reverse osmosis systems).

“PRM has substantial expertise and infrastructure to support the roll-out and manufacturing of our cleantech systems. This relationship will allow us to more readily meet the growing demand for our systems and expand our reach into the market. We have already begun scoping our first project together,” says Randall Moore, President of BioLargo Engineering, Science & Technologies (BioLargo’s engineering subsidiary – www.BioLargoEngineering.com).

“BioLargo’s AEC and AOS technologies are unique and valuable tools for targeted removal of tough-to-treat water contaminants including PFAS and micropollutants, both of which currently lack effective and affordable options in the marketplace. We recognized in BioLargo a commitment to serve customers with technical excellence and reliable results. We look forward to working with the BioLargo team,” said Robert Phillips, Jr., President of Product Recovery Management.

 

About PRM:

Headquartered in Butner, NC. PRM was founded in 1990 by Mel and Brian Phillips. Originating as Phillips Electric Company in 1976, PRM is now a premier environmental remediation and landfill gas company with systems operating across the globe. PRM is an Original Equipment Manufacturer (OEM) of pollution control and other equipment, mainly focused on the Remediation and Landfill Industries. Their experiences and talents are well diversified.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Wednesday, 28 September 2022

BioLargo Launches New Website To Highlight PFAS Mitigation Solutions

Source - Water Online: https://www.wateronline.com/doc/biolargo-launches-new-website-to-highlight-pfas-mitigation-solutions-0001 


BioLargo, Inc., developer of innovative cleantech technologies that target tough water and air contamination challenges, has launched a new website to promote its line of systems and services that tackle water contaminated by per- and polyfluoroalkyl substances (PFAS). The company also announced that it will be available to discuss its PFAS mitigation tools with prospective customers and distributors at the upcoming WEFTEC conference and trade show in New Orleans from October 8-12, 2022.

PFAS are an expansive class of man-made chemicals that contaminate thousands of drinking water sources around the US, with links to numerous negative health effects including cancer, hormone dysfunction, developmental disorders, and more. Due to their extremely stable chemical structure, PFAS do not break down naturally in the environment or in humans, causing them to bioaccumulate and inflict health impacts slowly over time. Another consequence of their stability is that there are few effective tools for removing them from water and wastewater.

BioLargo developed its own treatment technology to remove PFAS from water and started the commercialization process last October. Its system, called the Aqueous Electrostatic Concentrator (AEC), works by separating PFAS compounds in an electric field and depositing them onto proprietary membranes. It has been proven to remove a wide number of PFAS compounds to below the level of detection, consuming as little as 30 cents per 1,000 gallons in electricity costs. Crucially, the AEC generates as little as 1/1000 the PFAS-laden solid waste compared to other treatment options like carbon filtration and ion exchange, making it a low-carbon treatment option for eco-conscious treatment operations.

BioLargo’s new website, https://www.bestpfastreatment.com/, highlights the AEC and BioLargo’s other PFAS mitigation solutions, including its PFAS testing program (a way to quickly and affordably determine a site’s PFAS contamination levels and appropriate treatment solutions). It also offers insights into its broader environmental engineering and system integration services.

The website aims to become an educational resource for industry users by hosting educational articles on PFAS contamination, which is an ever-evolving issue with complex regulatory and techno-economic considerations that shift nearly every week.

“Our goal is to become a resource for those facing PFAS issues,” says Tonya Chandler, Director of Commercialization for BioLargo, Inc. “The landscape of PFAS regulations and mitigation technologies changes day by day. We wanted to offer a place where the industry could learn more about PFAS and how to remove it.”

BioLargo staff will be attending WEFTEC, the foremost water and wastewater sector conference and trade show in New Orleans from October 8-12, 2022. They will be available to discuss PFAS, the AEC and the company’s other solutions . Interested parties in attendance are encouraged to reach out to BioLargo to arrange meetings using the following contact information:

Tonya Chandler, Director of Commercialization
Email: Tonya.chandler@biolargo.com
Phone: +1-608-397-8301

Friday, 19 August 2022

BioLargo sees 'a major opportunity' for PFAS unit as it reports a surge in second-quarter revenue

Source: Proactive Investors (https://www.proactiveinvestors.ca/companies/news/990601/biolargo-sees-a-major-opportunity-for-pfas-unit-as-it-reports-a-surge-in-second-quarter-revenue-990601.html


BioLargo Inc (OTCQB:BLGO) CEO Dennis Calvert takes Proactive's Stephen Gunnion through the company's second-quarter results, which show a 185% year-over-year jump in revenue to $1.32 million on the back of strong contributions from its engineering and environmental divisions.

Calvert telling Proactive that the company's PFAS (per- and polyfluoroalkyl substances) business is a major opportunity, and BioLargo is at the forefront of real environmental impact, working with channel partners to solve some of today’s toughest environmental challenges.

Tuesday, 16 August 2022

BioLargo Achieves 185% Growth to $1.3 Million Revenue for Second Quarter 2022, as Published in Quarterly Report

Quarterly Report highlighted by profitable operating subsidiaries, growth of white-label odor product sales, and large engineering projects

Westminster, CA – August 16, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its Quarterly Report on Form 10-Q for the period ended June 30, 2022, with the SEC yesterday (www.biolargo.com/sec-filings). Here the company has provided highlights from the quarterly report and a discussion of key business initiatives with the most potential to stimulate growth.

The company will hold an investor webcast on Wednesday, August 17, 2022, at 1:00 pm Pacific / 4:00 pm Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/46358

BioLargo’s President and CEO Dennis P. Calvert said, “We are proud of the entire BioLargo team working together and executing on all fronts as we continue growing the business through bigger and better projects. It has been incredible to watch our team land and expand into new client projects through great service and deliverables. PFAS is a major opportunity for us, and we are on the forefront of real environmental impact, working with channel partners to solve some of today’s toughest environmental challenges.”

Financial highlights

  • Company-wide consolidated revenue for the three and six months ended June 30, 2022, was $1,323,000 and $2,287,000, which is a 185% and 121% increase over the same periods in 2021; revenue this quarter was a 37% increase compared with the first quarter of 2022.
  • Revenues from ONM Environmental, the company’s odor and VOC control subsidiary, for the three and six months ended June 30, 2022, were $700,000 and $1,300,000, an increase of $344,000 and $658,000, from the same periods in 2021. In the second quarter of 2022, this subsidiary generated a net operating income of $11,000, compared to a net operating loss of $107,000 in the same period of 2021.
  • Revenues from third parties for BioLargo Engineering, Science & Technologies, the company’s environmental engineering subsidiary, for the three and six months ended June 30, 2022, were $617,000 and $972,000, an increase of $434,000 and $698,000, from the same periods in 2021. In the second quarter of 2022, this subsidiary generated a net operating income of $56,000, compared to a net operating loss of $190,000 in the same period of 2021.

Commercial and developmental highlights

  • First PFAS customer – the company recently secured its first PFAS customer. As part of this project, BioLargo will engineer a comprehensive PFAS mitigation plan for an industrial site, and has signed an agreement with a new channel partner to sell the company’s PFAS treatment equipment and engineering services.
  • Ikigai’s POOPH – The company’s white-label pet odor control product partnership with Ikigai is advancing well and generating increasing revenues both from manufacturing the product and from license royalties. Sales thus far have exceeded early expectations, and the company’s partners at Ikigai are confident that growth will continue, especially as they push to get the product onto shelves at major retailers.
  • Garratt-Callahan partnership – The company expects first sales of the “minimal liquid discharge” (MLD) wastewater treatment equipment developed in partnership with Garratt-Callahan to begin soon, following discussions with an expanding list of Garratt-Callahan customers.
  • Larger engineering projects – In this quarter, BioLargo Engineering, Science & Technologies executed engineering projects for new customers, including its project to develop prototypes with Ultra Safe Nuclear, and the waste-to-energy plant project in South America. With both of these projects, early phase work is nearly done, and management anticipates that additional phases will soon begin, with the scope of work and level of engagement expanding.

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Friday, 12 August 2022

BioLargo Q2 2022 Earnings Results Webcast and Conference Call on Wednesday, August 17, 2022 - 4 PM Eastern Time

Westminster, CA – August 12, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company announced it will host an investor webcast and conference call on Wednesday August 17, 2022, at 1:00 pm Pacific / 4:00 pm Eastern. The event, which will be open to the public, will be held to review the company’s financial results for the three and six months ended June 30, 2022, discuss recent milestones and ongoing business initiatives, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio/video software.

 

To participate in the live webcast and teleconference:

Webcast Link:

https://www.webcaster4.com/Webcast/Page/2448/46358

Teleconference Domestic:

888-506-0062

Teleconference International:

Participant Access Code:

973-528-0011

656092

 

To watch or listen to a replay of the webcast or teleconference:

 

Webcast Replay Expiration:

Thursday, August 17, 2023

Teleconference Replay Expiration:

Wednesday, August 31, 2022

Teleconference Replay Domestic:

877-481-4010

Teleconference Replay International:

919-882-2331

Replay Passcode:

46358

 

The webcast replay and accompanying presentation materials will be made available on the Investor Relations section of BioLargo’s website at www.biolargo.com/investor-relations.

 

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Thursday, 11 August 2022

BioLargo Secures First PFAS Mitigation Customer and Signs New Channel Partner for PFAS Remediation

Westminster, CA – August 11, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, today announced that it has secured its first customer to engineer a comprehensive PFAS mitigation plan for an industrial site, and has signed an agreement with a new channel partner to sell the company’s PFAS treatment equipment and engineering services.

Per- and polyfluoroalkyl substances (PFAS) are man-made persistent, bioaccumulative chemicals linked to widespread negative health effects including cancer, birth defects, and more. They are known to contaminate surface and groundwater in all 50 states, affecting multiple industries. Through its environmental engineering subsidiary BioLargo Engineering, Science & Technologies, BioLargo offers PFAS mitigation services including field testing, engineering design, system installation, operation, and maintenance, as well as water treatment systems including the company’s own proprietary PFAS treatment technology the Aqueous Electrostatic Concentrator (AEC).

The customer contract is for the first phase of what is expected to be a multi-phase comprehensive PFAS remediation project. The contract was secured in collaboration with a new channel partner, which has been appointed to promote, market, and distribute BioLargo’s water treatment equipment and PFAS-related engineering and project integration services.

BioLargo’s President and CEO Dennis P. Calvert said, “Securing our first customer is obviously a very important step for BioLargo as a comprehensive solutions-provider in the PFAS remediation market. We will look forward to sharing more information about this project as well as our other activities with channel partners in the PFAS mitigation space.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Thursday, 4 August 2022

Proactive Investors Interview: BioLargo says it will report record quarterly revenue, with more record quarters to follow

Source: Proactive Investors (https://www.proactiveinvestors.ca/companies/news/989295/biolargo-says-it-will-report-record-quarterly-revenue-with-more-record-quarters-to-follow-989295.html 

BioLargo Inc (OTCQB:BLGO) CEO Dennis Calvert says a 37% quarter-over-quarter increase in second-quarter revenue to around $1.3 million is "the culmination of a lot of work".

"It really is the moment in which we are seeing some pretty dramatic percentage increases," Calvert told Proactive.

In part, Calvert attributed the quarterly gains to expanded sales of pet control products and wastewater treatment technologies.

"The number are getting more and more ... meaningful," he added. "Two of our operating units we reported on last quarter were teetering on profitability. We're pretty sure we've now achieved that objective."

Wednesday, 3 August 2022

BioLargo Sets New Quarterly Revenue Record

Quarterly revenues in Q2 grew 37% compared to Q1, and 185% compared to Q2 of 2021.

Westminster, CA – August 3, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, today announced that it has set a new quarterly revenue record, and provided a snapshot of the improving financial results of its environmental technology subsidiaries.

The company’s President and CEO Dennis P. Calvert said, “While we are pleased with our financial results from this quarter, we believe this is just the start of dramatic growth for our company, driven by (i) the expanded sales and expected retail launch of POOPH by our white-label pet odor control partners at Ikigai, (ii) the anticipated launch of our proprietary PFAS treatment technology, as well as the wastewater treatment product developed in partnership with Garratt-Callahan, and (iii) the expansion of big engineering projects like the waste-to-energy conversion plant project in South America.”

He continued, “It is also worth mentioning that our project to help a national nuclear fuel innovator develop prototype production systems is expected to expand over the coming months following a successful first phase of our contract.” You can read more about this project in the original press release, linked here: https://biolargo.blogspot.com/2022/06/biolargo-engineering-science.html.

BioLargo generated approximately $1.3 million in company-wide revenue for the second quarter of 2022, representing a 37% increase compared with the first quarter of 2022, and a 185% increase compared with the second quarter of 2021. Note, however, that these revenue figures are preliminary, have not been reviewed and are subject to change pending review by the company’s independent registered public accounting firm. The company will include its full results of operations in its quarterly report for the period ended June 30, 2022, due to be filed with the SEC by August 15, 2022. The company also intends to hold an investor webcast and conference call shortly after the filing of its quarterly report to discuss its financial results, and will provide details for participating in this event as soon as its available.  

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Thursday, 30 June 2022

BioLargo Engineering, Science & Technologies Selected to Help Make Novel Nuclear Reactor Fuel Production System

Westminster, CA – June 30, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that its engineering subsidiary located in Oak Ridge, Tennessee, has been working with Ultra Safe Nuclear to help produce the first prototype fuel production systems for the company’s revolutionary new Micro Modular Reactor (MMR®).

A Seattle-based nuclear energy innovator, Ultra Safe Nuclear has invented a “fission battery” – a fourth generation modular nuclear reactor – that can deliver safe, zero-carbon, cost-effective energy anywhere. The MMR® uses ceramic-encapsulated nuclear fuel – Fully Ceramic Micro-encapsulated (FCM®) – an extremely rugged and stable fuel with extraordinary high temperature stability.

Ultra Safe Nuclear recently opened a facility in Oak Ridge, Tennessee, and reports that it will invest approximately $13 million in the community. The facility is focused on building production systems that can efficiently manufacture the ceramic-encapsulated nuclear fuel used in their reactors.

BioLargo Engineering, Science & Technologies (BioLargo Engineering) has been retained to provide engineering design support, fabrication, and integration for the company’s prototype fuel production systems. Thus far, BioLargo has been contracted for work in the range of a half million dollars, to be completed over several months.

Randall Moore, President of BioLargo Engineering, said, “Ultra Safe Nuclear’s reactor represents the cutting edge in clean, safe nuclear energy. At BioLargo, we are focused on sustainable, clean technologies, and we’re thrilled to assist in developing the fuel systems for this impressive technology. We look forward to a long and fruitful relationship with Ultra Safe Nuclear.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

About Ultra Safe Nuclear Corporation

Ultra Safe Nuclear is the Seattle-based global leader in the deployment of micro reactors, and a strong vertical integrator of nuclear power technologies, entirely committed to bringing safe, commercially competitive, clean and reliable nuclear energy to markets throughout the world. The company adheres to strict inherent and intrinsic safety principles through technological innovation in fuels, materials and design: Ultra Safe Nuclear is Reliable Zero-Carbon Energy. Anywhere.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Monday, 27 June 2022

BioLargo Appearance on Benzinga All Access

BioLargo appeared on Benzinga's All Access YouTube show on Friday - you can watch right here!

Thanks Zunaid and the rest of the team at Benzinga for the great interview and the great show.



Thursday, 16 June 2022

BioLargo AEC Promotional Video

The Aqueous Electrostatic Concentrator (AEC) is BioLargo's technology that removes per- and polyfluoroalkyl substances (PFAS) from water. The AEC removes more than 99% of PFAS from flowing water and produces less than 1/1000 the PFAS-laden solid waste compared to other common treatment technologies.

Per and polyfluoroalkyl substances (PFAS) are man-made, persistent, bioaccumulative chemicals now known to have links to widespread negative health effects including cancer and reproductive problems. The Biden Administration has made remediation of PFAS-contaminated drinking water a priority, escalating regulations as part of their PFAS Roadmap.

Learn more at www.biolargoengineering.com/biolargo-aec.

Wednesday, 15 June 2022

(Video presentation) BioLargo Inc presenting at the Proactive One2One Virtual Forum - 14th June 2022

BioLargo Inc (OTCQB:BLGO)'s Dennis Calvert, CEO presenting at the Proactive One2One Virtual Forum.

BioLargo Inc invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control.

The company accomplishes this by providing the capital, support, and expertise to expedite these disruptive technologies from "cradle" to "maturity".

Monday, 23 May 2022

BioLargo, Inc. Discusses Record-Breaking Quarter on The Stock Day Podcast

Source: Stock Day Media - https://www.newsfilecorp.com/release/124951/BioLargo-Inc.-Discusses-RecordBreaking-Quarter-on-The-Stock-Day-Podcast 


Phoenix, Arizona--(Newsfile Corp. - May 23, 2022) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO), a company that invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. President and CEO of BioLargo, Dennis P. Calvert, joined Stock Day host Sever Oakley for an interview on the Stock Day Podcast.

Oakley began by asking about the company's background and vision. "BioLargo has over a decade of R&D behind it, and we've been inventing chemistries, technical solutions, and all sorts of innovations to help solve some of the biggest problems that face our planet, including clean air, clean water, and a cleaner Earth," explained Calvert. "All of that R&D is beginning to pay off through commercialization."

Oakley then commented on the company's recently announced record-breaking quarter and asked about the drivers behind this success. "Most of this is organic growth, so it is a very exciting time," answered Calvert. "It was a 69% growth over last year's quarter," he added, noting that the company brought in nearly a million in revenue in the first quarter of 2022.

The conversation then turned to the company's technology that treats water contaminated with per- and polyfluoroalkyl substances (PFAS). Calvert explained, "PFAS are 'forever chemicals' which have been used for about 35 years in all sorts of plastic coatings… PFAS has been linked to adverse health effects, including cancer." He added, "We have an innovation that we believe will be the number one technical solution for concentrating, extracting, and removing those contaminants from nature."

"What is the status of your PFAS treatment technology division?" asked Oakley. "We've just completed some testing with one of the largest [municipal water agencies] in the world, and that data and proof of claim has become instrumental," said Calvert. "We achieved what is called a non-detect status, which means the level was so low that it was below the level of being detectable by current technology," he said, before elaborating on the company's growing list of prospects and channel partners, as well as a pipeline of potential projects.

Oakley then turned the conversation to BioLargo's partnership with Garratt-Callahan, the largest privately owned water treatment company in North America. The two companies have partnered to bring a new wastewater treatment technology to market. "We have developed a system that has been validated, which we call the Minimum Liquid Discharge (MLD) [system]," said Calvert. "Garratt-Callahan asked us to design, make, and prove up this machine, and in exchange we would become the supply chain partner and they would manage distribution."

Calvert discussed the plan for rolling out the MLD system with Garratt-Callahan customers, "We are in current negotiations with customers… It is about a year and a half of work coming to fruition on the commercial side and we're pretty excited about the next few steps."

"Could you tell us about the new contract with the waste-to-energy conversion plant project in South America?" asked Oakley. Calvert explained that BioLargo has been contracted for the first phase of the project, a comprehensive project planning stage (i.e., "feasibility study"), and may be hired for additional stages with greater potential value. He finished by adding that if the project advances to completion, the total project cost could reach a half billion dollars over its lifetime of four or more years.

To hear Dennis Calvert's entire interview, follow the link to the podcast here: https://audioboom.com/posts/8088354-biolargo-inc-discusses-record-breaking-quarter-on-the-stock-day-podcast

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/

About BioLargo, Inc.

BioLargo, Inc. (OTCQB: BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as "we believe". These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

SOURCE:

Stock Day Media
(602) 821-1102

Tuesday, 17 May 2022

BioLargo’s First Quarterly Report of 2022 Highlights: Record Company-wide Revenues, Subsidiaries Achieving and Approaching Profitability, and Progress of Key Growth Catalysts

Westminster, CA – May 17, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its Quarterly Report on Form 10-Q for the period ended March 31, 2022, with the SEC yesterday (www.biolargo.com/sec-filings). Here the company has provided highlights from the report as well as commentary on the company’s strategy for growth.

“BioLargo is at a turning point,” said the company’s President and CEO, Dennis P. Calvert. “After investing years and millions of dollars into R&D for our innovative technologies, in this quarter we generated record revenues, our subsidiary ONM Environmental turned an operating profit, and our engineering subsidiary ended the quarter just shy of profitability. Although we have solidified our reputation as a trusted and credible cleantech solutions provider thanks to our commitment to creating best-in-class sustainable technologies and our growing roster of talented engineers and scientists, we still must work hard to continue to achieve these results in the long term. Now we are capitalizing on these assets in a way we believe will create significant value for our company and stockholders.”

The company is holding an investor webcast on Thursday, May 19, 2022, at 1:00 pm Pacific / 4:00 pm Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/45648  

Financial highlights

  • Company-wide revenues for the three months ended March 31, 2022, was a record $965,000, which is 69% higher than in the same period in 2021.
  • BioLargo subsidiary ONM Environmental’s revenue was $598,000, representing an 87% increase compared to the same period in 2021, and operating income was $13,000, representing its first-ever profitable quarter.
  • BioLargo Engineering, Science & Technologies generated $355,000 of revenue, representing a 177% increase compared to the same period in 2021. This subsidiary had an operating loss of $35,000 for the quarter, compared with an operating loss of $183,000 in the same period in 2021.

Please see management’s discussion and analysis of the company’s results of operations in its most recent Form 10-Q filed with the SEC on May 16, 2022, and the Risk Factors section in the company’s Form 10-K filed with the SEC on March 31, 2022, for more information.

Commercial and developmental highlights

  • PFAS – the AEC: The company has successfully completed in-house pilot testing of its sustainable, low-waste solution (the AEC) for treating water contaminated with per- and polyfluoroalkyl substances (PFAS), so-called “forever chemicals” linked to cancer, birth defects and diverse health problems. Based on those results and on demonstration of the AEC’s long-lasting performance without significant deterioration, the company is preparing a plan for an on-site commercial trial with a large municipal agency in Southern California. The company is also in discussions with potential industrial clients that it believes can safely rely upon the AEC’s proof of performance claims achieved in its water lab in Oak Ridge, TN rather than requiring field demonstration pilots. As a result of the company’s initial and limited marketing efforts, it has established a pipeline of potential customers that could exceed $90 million in value over time, subject to the company’s ability to stage-in this level of growth. Although management is highly encouraged and working to turn these prospective customers into clients, they are still at the early stage of the commercial process on each. Additionally, the company is negotiating three channel partner agreements for the AEC.
  • Private-label growth: BioLargo’s private label pet odor control product partnership with Ikigai Marketing Works, LLC is advancing steadily after the product was well-received in its television test-marketing campaign. Initial sales have exceeded expectations, and Ikigai is preparing to launch the product with multiple retail outlets.
  • Channel partner – Garratt-Callahan: The "minimal liquid discharge” water treatment system, invented by the 100+ year old water treatment company Garratt-Callahan and manufactured by BioLargo, has passed factory acceptance testing. Now, both companies are working closely to organize the commercial rollout of the equipment to first Garratt-Callahan customers, and believe that the proof-of-claim work already accomplished is sufficient for commercial sales activity to commence.
  • Waste-to-energy plant project: BioLargo’s engineering subsidiary has been hired to complete a comprehensive project feasibility plan for a waste-to-energy conversion plant project in South America. The proposed plant would process over two million tons of municipal solid waste annually, and the project cost is likely to exceed $500 million in total, with the engineering design portion expected at 10% of that amount. So far, BioLargo has been contracted for the first phase of the project (i.e., feasibility study), and while not guaranteed, expects to be involved in subsequent phases if the project moves forward as planned.

BioLargo CEO Dennis P. Calvert added, “In many ways, the hardest work is done: inventing, developing, and commercially validating our innovations. Now, we have multiple channel partnerships already contracted and executing as planned to foster expanded revenue growth. We believe that as this strategy matures and expands, our commercial business units will have the potential to generate positive cash flow on a segment basis, and ultimately, positive cash flow for the company as a whole. We are very excited about the Garratt-Callahan project going commercial and our PFAS solution heading into its first projects. The response from the market has been extremely validating for both of these projects.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Q1 2022 Earnings Results Webcast and Conference Call on Thursday, May 19, 2022 – 4:00 PM Eastern Time

Westminster, CA – May 17, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of cleantech technologies and full-service environmental engineering company, announced it will host an investor webcast and conference call on Thursday May 19, 2022, at 1:00 pm Pacific Time / 4:00 pm Eastern Time. The event, which will be open to the public, will be held to review the company’s financial results for the three months ended March 31, 2022, discuss recent milestones and upcoming projects, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio video software.
 
To participate in the live webcast and teleconference:

Webcast Link:

https://www.webcaster4.com/Webcast/Page/2448/45648

Teleconference Domestic:

888-506-0062

Teleconference International:

Participant Access Code:

973-528-0011

784818

 
To watch or listen to a replay of the webcast or teleconference:
 

Webcast Replay Expiration:

Friday, May 19, 2023

Teleconference Replay Expiration:

Thursday, June 02, 2022

Teleconference Replay Domestic:

877-481-4010

Teleconference Replay International:

919-882-2331

Replay Passcode:

45648

 
The webcast replay and accompanying presentation materials will be made available on the Investor Relations section of BioLargo’s website at www.biolargo.com/investor-relations.

 

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

 Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Wednesday, 20 April 2022

BioLargo Continues Growth Trend by Breaking Quarterly Revenue Record

Westminster, CA – April 20, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, today announced a company-wide quarterly revenue record for the first quarter of 2022. The company also announced it had been awarded the initial contract for a waste-to-energy conversion plant project.

New company-wide quarterly revenue record

BioLargo generated approximately $900,000 in revenue (company-wide) for the first quarter of 2022, representing an approximate 60% increase compared with the same period in 2021. Leading the way was subsidiary ONM Environmental with a new quarterly revenue record of approximately $550,000, and BioLargo’s engineering subsidiary with quarterly revenue of approximately $350,000, while it continued to support R&D on the company’s patented technologies. With these revenues, each of ONM Environmental and BioLargo Engineering moved closer to generating an operating profit. Note however, these preliminary revenue figures have not been reviewed, and are subject to change pending review by the company’s independent registered public accounting firm; the company will include its full results of operations in its quarterly report, which it intends to file with the SEC on about May 16, 2022.

Feasibility contract awarded for potential large waste-to-energy conversion plant project

BioLargo Engineering has been retained to conduct a feasibility study by a Southern California based sustainable energy services company intending to build a waste-to-energy conversion plant in South America. The site of the proposed conversion plant is approximately 296 acres, where it is planned to process over two million tons of municipal solid waste annually. A feasibility study is typically the first step in the design process for a new project of this size, and will address multiple fundamental factors that will influence the design and operation of the anticipated facility, including technology options, rough costs to construct and operate, environmental impacts, and rough equipment sizing. The feasibility study would then inform and facilitate the development of a design basis document, then conceptual design, and ultimately the front-end engineering design. Thus far, BioLargo’s engineers have been contracted on the feasibility study only, but expect to be involved in subsequent phases should the project move forward as planned.

BioLargo’s air quality control division (ONM Environmental), with a significant client base in the waste handling industry, was critical in bringing this project to the company and will work with BioLargo’s engineers to execute this project. ONM Environmental brings to the table a team with extensive expertise surrounding the design and operation of waste handling facilities, and BioLargo Engineering brings a team of veteran engineers with decades of experience designing and integrating complex projects as well as specific expertise in the area of waste-to-energy conversion.

Randall Moore, President of BioLargo Engineering, Science & Technologies, said, “The development of this waste-to-energy conversion plant is directly in our wheelhouse of past experience and knowledge. To process two million tons of municipal solid waste per year, the total capital outlay by the developer for a processing plant of that size could exceed $500 million, with the potential to keep our team busy for the next four years.”

Dennis P. Calvert, President and CEO of BioLargo, commented, “We look forward to sharing additional information as this project advances. We are continuing our strategy of employing strategic partnerships to develop new revenue channels for our cleantech products and services. As we referenced in our recently published annual report, we have additional channel partnerships in various stages of negotiation for our PFAS treatment system and are eager to provide more information soon. When combined with our other partnerships aimed at delivering cleantech solutions, including with Garratt-Callahan and Ikigai, we believe these record revenues are the beginning of what we believe will be accelerated growth for our company.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.